SCHEDULE: Perceptive Advisors Discloses 9.99% Stake in Orchestra BioMed
Beneficial Ownership Disclosure
Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund collectively reported a 9.99% beneficial ownership stake in Orchestra BioMed Holdings, Inc.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") beneficially own 5,679,480 shares of Orchestra BioMed Holdings, Inc. Common Stock.
- This represents 9.99% of the Issuer's outstanding Common Stock.
- The ownership percentage is calculated based on 56,464,731 shares outstanding as of November 6, 2025, and includes the assumed exercise of 386,924 Pre-Funded Warrants.
- The Master Fund directly holds 5,292,556 shares of Common Stock and 1,500,000 Pre-Funded Warrants, immediately exercisable at an exercise price of $0.0001 per share.
- A Beneficial Ownership Limitation prevents the exercise of Pre-Funded Warrants if it would result in the Reporting Persons owning more than 9.99% of the outstanding shares.
- Perceptive Advisors serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
Sentiment
Score: 7
Explanation: The filing indicates a significant, stable institutional ownership stake by a specialized life sciences investor, which is generally a positive signal of confidence. The maintenance of a 9.99% stake, limited by beneficial ownership rules, suggests a strategic long-term position without seeking control.
Positives
- A significant institutional investor, Perceptive Advisors, maintains a substantial stake, indicating continued confidence in Orchestra BioMed Holdings, Inc.
- The beneficial ownership limitation on warrants suggests a strategic approach to maintaining a significant but non-controlling stake, potentially avoiding certain regulatory thresholds or signaling a long-term investment horizon.
Risks
- The Beneficial Ownership Limitation on Pre-Funded Warrants restricts the Reporting Persons from increasing their stake beyond 9.99% through warrant exercise, potentially limiting their upside if the stock performs exceptionally well and they wish to increase exposure.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the Issuer's operational or financial performance.
Industry Context
Perceptive Advisors is a prominent investment firm specializing in the life sciences sector. Their significant stake in Orchestra BioMed Holdings, a company likely operating in the biotech or healthcare industry, suggests a strategic investment in a company within their core focus area. Such an investment by a specialized fund can be seen as a vote of confidence in the company's potential within the competitive life sciences landscape.
Stakeholder Impact
- Shareholders: The continued significant ownership by a reputable institutional investor like Perceptive Advisors may instill confidence among existing and potential shareholders, signaling a belief in the company's long-term value.
- Management: The presence of a large, non-controlling institutional investor can provide a level of oversight and strategic input, potentially influencing management decisions.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires filing of this statement. |
| 11/06/2025 | Date as of which 56,464,731 shares of Common Stock were reported outstanding in the Issuer's Quarterly Report on Form 10-Q. |
| 11/10/2025 | Date the Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 11/14/2025 | Date of signing of this Schedule 13G filing. |
Recommendation
holdThe filing is a routine Schedule 13G amendment disclosing a significant, stable beneficial ownership stake by Perceptive Advisors. It does not contain new operational or financial information that would fundamentally alter the investment thesis for Orchestra BioMed. The continued presence of a major institutional investor is a positive signal, but without additional company-specific news or financial updates, a 'hold' recommendation is appropriate for existing investors. New investors would need to conduct further due diligence beyond this ownership disclosure.
Keywords
Orchestra BioMed Holdings, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Institutional Investor, Biotech, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.